5/16
10:10 am
tcrx
Rating for TCRX
Low
Report
Rating for TCRX
5/16
08:37 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $12.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $12.00 price target on the stock.
5/14
08:06 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
High
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
5/13
06:43 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
High
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
5/13
06:43 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
High
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
5/13
08:09 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Medium
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
5/13
06:23 am
tcrx
Rating for TCRX
Low
Report
Rating for TCRX
5/13
06:23 am
tcrx
Rating for TCRX
Low
Report
Rating for TCRX
4/23
01:33 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
4/23
01:33 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
4/23
01:15 pm
tcrx
Rating for TCRX
Low
Report
Rating for TCRX
4/23
01:15 pm
tcrx
Rating for TCRX
Low
Report
Rating for TCRX
4/17
03:11 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
4/17
03:11 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
3/7
11:24 am
tcrx
Rating for TCRX
Low
Report
Rating for TCRX
3/7
11:24 am
tcrx
Rating for TCRX
Low
Report
Rating for TCRX
3/6
11:54 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, up previously from $9.00.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, up previously from $9.00.
3/6
11:54 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, up previously from $9.00.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, up previously from $9.00.